Skip to content

8-KAccepted Oct 21, 9:07 PM ET

Supernus Pharmaceuticals: FDA recognizes 7 years orphan-drug exclusivity

SUPERNUS PHARMACEUTICALS, INC.

Accepted (ET)

9:07 PM

Oct 21, 2026

Filed

Oct 22, 2026

Documents

13

Size

212.6 KB

Summary

Supernus Pharmaceuticals: FDA recognizes 7 years orphan-drug exclusivity

Updated

What happened On Oct 21, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. The filing states the seven-year market exclusivity for ONAPGO began on Feb 3, 2025, the date of FDA approval. The company also announced it submitted a supplemental new drug application to the FDA for a second supplier for ONAPGO and continues to expect potential FDA approval of the second supplier by mid-year 2027.

Key details

  • Seven years of market exclusivity for ONAPGO began on Feb 3, 2025 (date of FDA approval).
  • ONAPGO is apomorphine HCl for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.
  • Company submitted a supplemental new drug application for a second supplier and expects potential FDA approval by mid-year 2027.
  • Press release dated Oct 21, 2026; current report on Form 8-K filed Oct 22, 2026.

Why it may matter This report is Item 8.01 (other events) and covers the company announcement that the FDA has recognized seven years of orphan-drug exclusivity for ONAPGO and the submission of a supplemental NDA for a second supplier.

This filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing